RAPTOR PHARMACEUTICAL ANNOUNCED FINAL DATA ANALYSIS WILL COMMENCE FOR ITS PHASE 3 CLINIAL TRIAL THIS WEEK (RPTP)

Raptor Pharmaceutical (NASDAQ:RPTP) announced that on June 3 the last clinical trial patient visits were completed and final data analysis will commence this week for its Phase 3 clinical trial of its delayed-release oral formulation of cysteamine bitartrate in patients with nephropathic cystinosis.

"We are pleased to see our final patients complete the Phase 3 clinical trial and are gratified that 40 of the 41 patients completing the study have elected to enter our long-term extension study in which they have chosen to remain on the twice-a-day DR Cysteamine formulation," commented Patrice Rioux M.D., Ph.D., CMO of Raptor. "As our earliest enrolled patients began to enter the extension study in August of last year, some patients have now been treated with DR Cysteamine for over 9 months; we currently have over 6 months of extension data on our first 20 patients."

The company is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise.